Journal of Cytology & Histology

Satoshi Matsusaka

Publications

• Research Article
  CD133-positive Status Predicts Better Prognosis in Metastatic Colorectal Cancer Patients Treated with Cetuximab
  Author(s): Dai Inoue, Satoshi Matsusaka, Noiriko Yamamoto, Mitsukuni Suenaga, Eiji Shinozaki, Nobuyuki Mizunuma, Yuichi Ishikawa and Kiyohiko HatakeDai Inoue, Satoshi Matsusaka, Noiriko Yamamoto, Mitsukuni Suenaga, Eiji Shinozaki, Nobuyuki Mizunuma, Yuichi Ishikawa and Kiyohiko Hatake
  
  Background: There are few evidence which kind of tumor is more benefit from cetuximab, more investigations of supplementary predictive factors are highly relevant. The purpose is to evaluate the prognostic significance of CD133 expression and to investigate the utility as biomarker of prognosis of metastatic colorectal cancer (mCRC) patients treated with cetuximab. Methods: We investigated progression-free survival (PFS) and overall survival (OS) of patients with mCRC about 5FU-based regimen as first line chemotherapy and cetuximab as salvage line retrospectively, and performed immunohistochemical staining to evaluate the CD133 status. Non-parametric statistics, univariate and multivariate analysis were used. Results: From October 2008 to June 2009, 46 patients with measurable mCRC had received cetuximab as salvage line, and all of them had treated with 5FU-based regimen as first line.. Read More»
  DOI: 10.4172/2157-7099.1000202

  Abstract PDF